CN Mobile Logo


Genitourinary Cancers

Genitourinary Cancers

Declines in the rates of cigarette smoking in several states mirrored declines in prostate cancer deaths between 1999 and 2010, according to a new epidemiologic analysis.

Prostate cancer patients who kept up a moderate to high level of physical activity had better survival prognoses compared with their more sedentary counterparts.

Afatinib showed significant activity in a phase II trial of patients with metastatic platinum-refractory urothelial carcinoma, and patients with HER2 or ERBB3 alterations had significantly better outcomes.

Combination therapy with bicalutamide and everolimus resulted in promising responses in a phase II trial of patients with castration-resistant prostate cancer, though a substantial proportion of patients experienced everolimus-related toxicities.

Men who receive pharmacologic androgen deprivation therapy as part of their treatment for prostate cancer may be at higher risk for depression.

Results of a phase II randomized trial found that combining a short course of androgen deprivation therapy with bevacizumab improved relapse-free survival in men with hormone-sensitive prostate cancer.

Using simulation modeling, researchers found that PSA screening can be cost-effective if men with low-risk prostate cancer do not undergo treatment and if clinicians use restrictive criteria to make a decision to biopsy.


Subscribe to Genitourinary Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.